Efecto positivo de la suplementación con isoflavonas derivadas de la soya sobre síntomas menopáusicos
DOI:
https://doi.org/10.18041/1900-7841/rcslibre.2016v11n1.1620Palabras clave:
Escala de puntuación de la menopausia, Isoflavonas, Postmenopausia, Soya, SuplementaciónResumen
Antecedente: En los últimos años han aumentado los tratamientos alternativos para el manejo de los síntomas de la menopausia, sobre todo en poblaciones de alto riesgo que tienen contraindicaciones para el uso de estrógenos. Objetivo: Evaluar el efecto de la suplementación con isoflavonas derivadas de la soya sobre síntomas climatéricos en mujeres postmenopáusicas. Método: Sesenta y seis mujeres postmenopáusicas entre 40 y 65 años de edad participaron en este estudio para recibir 50 mg/día de isoflavonas derivadas de soya durante 3 meses. Se evaluaron los síntomas de la menopausia al inicio del estudio y a los 45 y 90 días mediante la Escala de Puntuación de la Menopausia (MRS: Menopause Rating Scale). Resultados: La suplementación con isoflavonas derivadas de la soya tuvo un efecto positivo sobre síntomas de la menopausia. Así, los puntaje totales de la MRS disminuyeron significativamente de 23.0±8.7 (al basal) a 12.8±7 y 4.3±4.5 (45 y 90 días, respectivamente, ambos p<0.05). Se observó la misma tendencia para los puntajes de las sub-escalas del MRS (somática, psicológica y urogenital) y de cada uno de los síntomas componentes de las subescalas. Conclusión: En esta muestra de mujeres postmenopáusicas, la suplementación con isoflavonas derivadas de la soya ejerció un efecto positivo sobre los síntomas de la menopausia.Descargas
Referencias
Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. Maturitas. 2007; 57 (3): 271-8.
Blümel JE, Chedraui P, Baron G, Bencosme A, Calle A, Danckers L, et al. Collaborative Group for Research of the Climacteric in Latin America (REDLINC). Menopausal symptoms appear before the menopause and persist 5 years beyond: a detailed analysis of a multinational study. Climacteric. 2012; 15 (6): 542-51. doi: 10.3109/13697137.2012.658462
Chedraui P, Blümel JE, Baron G, Belzares E, Bencosme A, Calle A, et al. Impaired quality of life among middle aged women: a multicentre Latin American study. Maturitas. 2008; 61 (4): 323-9. doi: 10.1016/j.maturitas.2008.09.026
Hidalgo LA, Chedraui PA, Morocho N, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol. 2006; 22: 447-54.
Royer M, Castelo-Branco C, Blümel JE, Chedraui PA, Danckers L, Bencosme A, et al. Collaborative Group for Research of the Climacteric in Latin America. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric. 2007; 10 (2):164-70. doi:10.1080/13697130701258895
Chedraui P, Hidalgo L, Chavez D, Morocho N, Alvarado M, Huc A. Quality of life among postmenopausal Ecuadorian women participating in a metabolic syndrome screening program. Maturitas. 2007; 56 (1): 45-53. doi: 10.1016/j.maturitas.2006.05.008
Bhavnani BR, Strickler RC. Menopausal hormone therapy. J Obstet Gynaecol Can. 2005; 27: 137-62.
Baber RJ, Panay N, Fenton A. The IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19: 109-50.
Leon-Leon P, Chedraui P, Hidalgo L, Ortiz F, Castelo-Branco C. Hormone therapy for the management of the menopause in Ecuador: perception, use and knowledge among middle-aged women. Gynecol Endocrinol. 2008; 24: 580-5.
Castelo-Branco C, Rostro F. Management of menopause. Minerva Ginecol. 2006; 58: 137-52.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288 (3): 321-33.
Blümel JE, Chedraui P, Barón G, Benítez Z, Flores D, Espinoza MT, et al. Collaborative Group for Research of the Climacteric in Latin America (REDLINC). A multicentric study regarding the use of hormone therapy during female mid-age (REDLINC VI). Climacteric. 2014; 17: 433-41.
Vallejo MS, Witis S, Ojeda E, Mostajo D, Morera F, Meruvia N, et al. Does the menopausal status of female gynecologists affect their prescription of menopausal hormone therapy? Climacteric. 2016; 19 (4): 1-6.
Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol. 1993; 44: 37-43.
Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol. 2001; 78: 67-75.
Rees M. Alternative treatments for the menopause. Best Pract Res Clin Obstet Gynaecol. 2009; 23: 151-61.
Bitto A, Altavilla D, Bonaiuto A, Polito F, Minutoli L, Di Stefano V, et al. Effects of aglycone genistein in a rat experimental model of postmenopausal metabolic syndrome. J Endocrinol. 2009; 200: 367-76.
Chedraui P, San Miguel G, Schwager G. The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index. Gynecol Endocrinol. 2011; 27: 307-13.
Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes. 2003; 1: 28.
Aedo S, Porcile A, Irribarra C. Calidad de vida relacionada con el climaterio en una población chilena de mujeres saludables. Rev Chil Obstet Ginecol. 2006; 71: 402-9.
Blumel JE, Castelo-Branco C, Rocangliolo ME, Bifa L, Tacla X, Mamani L. Changes in body mass index around menopause: a population study of Chilean woman. Menopause. 2001; 8: 239-44.
Blumel JE, Castelo-Branco C, Chedraui PA, Binfa L, Dowlani B, Gómez MS, et al. Patients’ and clinicians’ attitudes after the Women’s Health Initiative Study. Menopause. 2004; 11: 57-61.
Chedraui P, Hidalgo L, Chávez D, Morocho N, Alvarado M, Huc A. Menopausal symptoms and associated risk factors among postmenopausal women screened for the metabolic syndrome. Arch Gynecol Obstet. 2007; 275: 161-8.
Gambacciani M, Pepe A. Vasomotor symptoms and cardiovascular risk. Climacteric. 2009; 12: 32-35.
Blümel JE, Fica J, Chedraui P, Mezones-Holguín E, Zúñiga MC, Witis S, et al. Sedentary lifestyle in middle-aged women is associated with severe menopausal symptoms and obesity. Menopause. 2016; 23 (5): 488-93.
Davis SR, Castelo-Branco C, Chedraui P, Lumsden MA, Nappi RE, Shah D, et al. Understanding weight gain at menopause. Climacteric. 2012; 15: 419-29.
Ferrari A. Soy extract phytoestrogens with high dose of isoflavones for menopausal symptoms. J Obstet Gynaecol Res. 2009; 35: 1083-90.
Nahas EA, Nahas-Neto J, Orsatti FL, Carvalho EP, Oliveira ML, Dias R. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas. 2007; 58: 249-58.
Pérez-Lopez FR, Chedraui P, Gilbert JJ, Pérez-Roncero G. Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women’s Health Initiative era. Fertil Steril. 2009; 64: 1171-86.
Pérez-López FR, Chedraui P, Haya J, Cuadros JL. Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas. 2009; 64: 67-79.
Llaneza P, González C, Fernández-Iñarrea J, Alonso A, Díaz-Fernández MJ, Arnott I, et al. Soy isoflavones, Mediterranean diet, and physical exercise in postmenopausal women with insulin resistance. Menopause. 2010; 17: 372-8.
Charles C, Yuskavage J, Carlson O, John M, Tagalicud AS, Maggio M, et al. Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women. Menopause. 2009; 16: 395-400.
Chedraui P, Escobar GS, Pérez-López FR, Palla G, Monlt-Guevara M, Cecchi E, et al. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014; 77 (4): 370-4.
